✦ LIBER ✦

Acquired QT interval prolongation and HERG: implications for drug discovery and development

✍ Scribed by Keith Finlayson; Harry J. Witchel; James McCulloch; John Sharkey

Book ID: 113584881
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 391 KB
Volume: 500
Category: Article
ISSN: 0014-2999
DOI: 10.1016/j.ejphar.2004.07.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The impact of drug-induced QT interval p

The impact of drug-induced QT interval prolongation on drug discovery and development

✍ Fermini, Bernard; Fossa, Anthony A. 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 224 KB

Drug-Induced QT-Interval Prolongation: C

Drug-Induced QT-Interval Prolongation: Considerations for Clinicians

✍ Dr. Edward C. Li; Dr. John S. Esterly; Dr. Shaunte Pohl; Dr. Shane D. Scott; Dr. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB

Drug-induced long QT syndrome: molecular

Drug-induced long QT syndrome: molecular mechanisms for congenital and acquired QT prolongation

✍ Pamela K. Mason; J. Paul Mounsey 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 298 KB

QT interval prolongation by non-cardiova

QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development

✍ William Crumb; Icilio Cavero 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 293 KB

Preferred QT Correction Formula for the

Preferred QT Correction Formula for the Assessment of Drug-Induced QT Interval Prolongation

✍ JOHN CHILADAKIS; ANDREAS KALOGEROPOULOS; PANAGIOTIS ARVANITIS; NIKOLAOS KOUTSOGI 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB

QT prolongation through hERG K+ channel

QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development

✍ Maurizio Recanatini; Elisabetta Poluzzi; Matteo Masetti; Andrea Cavalli; Fabrizi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 584 KB

## Abstract Prolongation of the QT interval of the electrocardiogram is a typical effect of Class III antiarrhythmic drugs, achieved through blockade of potassium channels. In the past decade, evidence has accrued that several classes of drugs used for non‐cardiovascular indications may prolong the